ReviewVisceral medicine2018
Immunodysfunction in Acute-on-Chronic Liver Failure.
Review in Visceral medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Sepsis Drives Severity and Mortality in Acute-on-Chronic Liver Failure Among ICU Patients with Alcohol-Related Cirrhosis: A Retrospective Single-Center Study.Journal of clinical medicine · 2025Article
- Association between neutrophil percentage to albumin ratio and short term prognosis of acute on chronic liver failure treated with artificial liver support system.Scientific reports · 2025Article
- Serum IL-17F as a biomarker of infection-independent cirrhosis progression.Frontiers in immunology · 2025Observational
- Extracellular vesicles of patients with acute-on-chronic liver failure induce mitochondrial dysfunction in T cells.Frontiers in immunology · 2025Article
- Efficacy of Granulocyte Colony-Stimulating Factor in Acute on Chronic Liver Failure: A Systematic Review and Survival Meta-Analysis.Journal of clinical medicine · 2023Review
- Implications of anaemia and response to anaemia treatment on outcomes in patients with cirrhosis.JHEP reports : innovation in hepatology · 2023Article
- The progress to establish optimal animal models for the study of acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- Cirrhosis-Based Acute-on-Chronic Liver Failure Is Marked by Inflammation and Impaired Liver Regeneration Despite Stat3 Activation.Gastro hep advances · 2022Article
- Targeted NMR-based serum metabolic profiling of serine, glycine and methionine in acute-on-chronic liver failure patients: Possible insights into mitochondrial dysfunction.Analytical science advances · 2021Article
- Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.Frontiers in medicine · 2021Review
- Metabolic defects in splenic B cell compartments from patients with liver cirrhosis.Cell death & disease · 2020Article
- Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity.Frontiers in immunology · 2020Article
- Immune Dysfunction and Albumin-Related Immunity in Liver Cirrhosis.Mediators of inflammation · 2019Review
- Acute-on-Chronic Liver Failure.Visceral medicine · 2018Article
- Intensive Care Therapy for Patients with Advanced Liver Diseases.Visceral medicine · 2018Review
- Granulocyte Colony-stimulating Factor Improves Innate Immunity in Pediatric Pretransplant Patients.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing evidence reveals a close and reciprocal link between acute-on-chronic liver failure (ACLF) and immunodysfunction.
methodsA literature search in PubMed and abstract databases of relevant congresses was performed.
resultsImportant characteristics of liver cirrhosis like tissue hypoxia, cell death, or bacterial translocation maintain a state of chronic inflammation. Precipitating events of ACLF such as infections or alcoholic hepatitis are capable of strongly augmenting cirrhosis-associated systemic inflammation to grades sufficient to induce ACLF-defining organ failures. Chronic systemic inflammation, however, is causally linked to profound immunosuppression. As a consequence, patients with liver cirrhosis and in particular with ACLF are at high risk for severe infections. Promising strategies to ameliorate immunodysfunction, like albumin substitution, administration of recombinant interleukin-22 or granulocyte colony-stimulating factor, antibiotic prophylaxis, or anticoagulation, are under development and offer the chance to specifically prevent and treat ACLF.
conclusionA better understanding of the immunopathology of ACLF will likely translate into the implementation of specific therapeutic modalities to prevent and overcome ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.